SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] and the options under the Equity Incentive Plan are not exercised), the following persons will have, or be deemed, or taken to have an interest and/or short position in the Shares or the underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company:

		Shares held as of the Latest Practicable Date		Shares held immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no further Shares issued under the Equity Incentive Plan)	
Name of Shareholder	**Nature of interest**	**Number of Shares(1)**	**Percentage of shareholding in our total issued share capital**	**Number of Shares(1)(2)**	**Percentage of shareholding in our total issued share capital(5)**
OrbiMed Asia GP IV, LP	Interest in a controlled corporation(2)	27,738,482	20.23%	[REDACTED]	[REDACTED]
OrbiMed Asia Partners IV, L.P.	Beneficial Interest	27,738,482	20.23%	[REDACTED]	[REDACTED]
OrbiMed Advisors IV Limited	Interest in a controlled corporation(2)	27,738,482	20.23%	[REDACTED]	[REDACTED]
OrbiMed Capital GP VIII LLC . .	Interest in a controlled corporation(3)	27,738,482	20.23%	[REDACTED]	[REDACTED]
OrbiMed Private Investments VIII, LP.	Beneficial interest	27,738,482	20.23%	[REDACTED]	[REDACTED]
OrbiMed Advisors LLC	Interest in a controlled corporation(2, 3)	55,476,964	40.46%	[REDACTED]	[REDACTED]
Creacion Ventures I, L.P.	Interest in a controlled corporation(4)	27,738,482	20.23%	[REDACTED]	[REDACTED]
Creacion Ventures GP I, LLC	Interest in a controlled corporation(4)	27,738,482	20.23%	[REDACTED]	[REDACTED]
Montar Capital, LLC	Beneficial interest	27,738,482	20.23%	[REDACTED]	[REDACTED]
Mr. Quanhong YUAN.	Interest in a controlled corporation(5)	3,676,464	2.68%	[REDACTED]	[REDACTED]
	Interest of Spouse(6)	15,254,607	11.12%	[REDACTED]	[REDACTED]
Ms. Meichai ZHANG (張媚釵)(6)	Interest in a controlled corporation(7)	15,254,607	11.12%	[REDACTED]	[REDACTED]
	Interest of Spouse(8)	3,676,464	2.68%	[REDACTED]	[REDACTED]

		Shares held as of the Latest Practicable Date		Shares held immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no further Shares issued under the Equity Incentive Plan)	
Name of Shareholder	**Nature of interest**	**Number of Shares(1)**	**Percentage of shareholding in our total issued share capital**	**Number of Shares(1)(2)**	**Percentage of shareholding in our total issued share capital(5)**
Image Frame Investment	Beneficial Interest	11,157,380	8.14%	[**REDACTED**]	[**REDACTED**]
Tencent(9)	Interest in controlled corporation	11,157,380	8.14%	[**REDACTED**]	[**REDACTED**]

Notes:

(1) The number of Shares held assuming that all of the Preferred Shares have been converted into the Shares on a one-to-one basis.

(2) As of the Latest Practicable Date, OrbiMed Asia GP IV, L.P. is the general partner of OrbiMed Asia Partners IV, L.P.; OrbiMed Advisors IV Limited is the general partner of OrbiMed Asia GP IV, L.P.. Additionally, OrbiMed Advisors LLC is the advisory company of OrbiMed Asia Partners IV, L.P. pursuant to the advisory agreement between the two entities which grants OrbiMed Advisors LLC voting power. Accordingly, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Limited, and OrbiMed Advisors LLC are deemed to be interested in the Shares held by OrbiMed Asia under the SFO.

(3) As of the Latest Practicable Date, OrbiMed Capital GP VIII LLC is the general partner of OrbiMed Private Investments VIII, LP; OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VIII LLC. Accordingly, OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC are deemed to be interested in the Shares held by OrbiMed U.S. under the SFO.

(4) Creacion Ventures GP I, LLC is the manager of Montar Capital, LLC. Creacion Ventures I, L.P. holds 90.8% limited partnership interest in Montar Capital, LLC. Accordingly, Creacion Ventures GP I, LLC and Creacion Ventures I, L.P. are deemed to be interested in the Shares held by Montar Capital, LLC under the SFO.

(5) As of the Latest Practicable Date, Splendid Biotech, beneficially owns 3,676,464 Shares, is managed by Pole Star Biotech LLC, which is ultimately owned by Mr. Quanhong Yuan, our non-executive Director. Accordingly, Mr. Quanhong Yuan is deemed to be interested in the Shares held by Splendid Biotech under the SFO.

(6) Ms. Quanhong Yuan is the spouse of Ms. Meichai Zhang. Accordingly, Mr. Quanhong Yuan is deemed to be interested in the Shares held by Ms. Zhang Meichai under the SFO.

(7) As of the Latest Practicable Date, Hankang Biotech, beneficially owns 14,696,738 Shares, is managed by Hankang Biotech III, LLC, which is ultimately owned by Ms. Meichai Zhang. Sky Future Investment, which beneficially owns 557,869 Shares, is wholly-owned by Ms. Meichai Zhang. Accordingly, Ms. Meichai Zhang is deemed to be interested in the Shares held by Hankang Biotech and Sky Future Investment under the SFO.

(8) Ms. Meichai Zhang is the spouse of Mr. Quanhong Yuan, our non-executive Director. Accordingly, Ms. Meichai Zhang is deemed to be interested in the Shares held by Mr. Quanhong Yuan under the SFO.

(9) As of the Latest Practicable Date, Image Frame Investment is a wholly-owned subsidiary of Tencent. Accordingly, Image Frame Investment is deemed to be interested in the Shares held by Image Frame Investment under the SFO.

Save as disclosed herein, our Directors are not aware of any person who will, immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] and the options under the Equity Incentive Plan are not exercised), have an interest or short position in the Shares or underlying Shares which will be required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company.